Volume : 10, Issue : 10, October – 2023

Title:

HUMAN PAPILLOMAVIRUS VACCINE, BENEFITS AND RECOMMENDATIONS – REVIEW

Authors :

Yousef Menwer Alsaedi, Abdullah abdulaziz turkistani , Mohammad menwer alsaedi, Fahad Talal ALSULAMI , Alwaleed Fayduallah ALIDRISS, Ahmed Suhail MAIMANI, Essam Abdoun Bassaif, Mohammd abdulaziz tarkistani, Hamda Daifullah ALAZWARI, HAFSAH HASSN ALI HAWSAWI

Abstract :

Vaccination to prevent HPV-related infection that leads to cancer, particularly cervical cancer, is a significant public health breakthrough. Narrative review conducted through literature, targeting relevant articles published up to the end of 2021, using the electronic databases such as PubMed and Embase. There are now two licensed HPV vaccinations available, both of which include recombinant virus-like particles of HPV types 16 and 18 (which cause over 70% of cervical cancer). In addition, one vaccine protects against HPV strains 6 and 11, which cause genital warts. The safety profile of both vaccines was extensively evaluated before to licensure in randomized controlled clinical trials, and it has been further elucidated following licensure by surveillance and particular research in large populations.

Cite This Article:

Please cite this article in press Yousef Menwer Alsaedi et al, Human Papillomavirus Vaccine, Benefits And Recommendations – Review, Indo Am. J. P. Sci, 2023; 10 (10).

Number of Downloads : 10

References:

1. Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group . Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394:497–509.
2. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 2020; 395:575–90.
3. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017; 141:664–70.
4. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(suppl 5):F123–38.
5. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915–27.
6. Paavonen J, Jenkins D, Bosch FX, et al.; HPV PATRICIA study group . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161–70.
7. Schiffman M, Castle PE, Jeronimo J, et al. Human papilloma- virus and cervical cancer. Lancet. 2007;370:890–907.
8. Chaturvedi AK. Beyond cervical cancer: burden of other HPV- related cancers among men and women. J Adolesc Health. 2010;46:S20–6.
9. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
10. Ferlay J, Shin H, Bray F, et al. GLOBOCAN 2008 v1. 2, cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer, 2010; 2012.
11. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24:S4–15.
12. Weinstock H, Berman S, Cates W Jr. Sexually transmitted dis- eases among American youth: incidence and prevalence esti- mates, 2000. Perspect Sexual Reprod health. 2004;36:6–10.
13. Da Ros CT, da Silva Schmitt C. Global epidemiology of sexu- ally transmitted diseases. Asian J Androl. 2008;10:110–4.
14. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8:1663–79.
15. Cutts F.T., Franceschi S., Goldie S., Castellsague X., de Sanjose S., Garnett G., Edmunds W.J., Claeys P., Goldenthal K.L., Harper D.M., et al. Human papillomavirus and HPV vaccines: A review. Bull. World Health Organ. 2007;85:719–726.
16. Zhang Q., Zheng R., Fu Y., Mu Q., Li J. Mental health consequences during alerting situations and recovering to a new normal of coronavirus epidemic in 2019: A cross-sectional study based on the affected population. BMC Public Health. 2021;21:1499.
17. Basu P., Malvi S.G., Joshi S., Bhatla N., Muwonge R., Lucas E., Verma Y., Esmy P.O., Poli U.R.R., Shah A., et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: A multicentre, prospective, cohort study. Lancet Oncol. 2021;22:1518–1529.
18. Kjaer S.K., Dehlendorff C., Belmonte F., Baandrup L. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J. Natl. Cancer Inst. 2021;113:1329–1335.
19. Gee J., Naleway A., Shui I., Baggs J., Yin R., Li R., Kulldorff M., Lewis E., Fireman B., Daley M.F., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279–8284.
20. Bonde U., Joergensen J.S., Lamont R.F., Mogensen O. Is HPV vaccination in pregnancy safe? Hum. Vaccines Immunother. 2016;12:1960–1964.
21. Angelo M.-G., Zima J., Tavares Da Silva F., Baril L., Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: More than 4 years of experience. Pharmacoepidemiol. Drug Saf. 2014;23:456–465.
22. Villa A., Patton L.L., Giuliano A.R., Estrich C.G., Pahlke S.C., O’Brien K.K., Lipman R.D., Araujo M.W.B. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews. J. Am. Dent. Assoc. 2020;151:245–254.
23. Malagón T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect. Dis. 2012;12:781–789.
24. Lukács A., Máté Z., Farkas N., Mikó A., Tenk J., Hegyi P., Németh B., Czumbel L.M., Wuttapon S., Kiss I., et al. The quadrivalent HPV vaccine is protective against genital warts: A meta-analysis. BMC Public Health. 2020;20:691.
25. Zhang X., Zeng Q., Cai W., Ruan W. Trends of cervical cancer at global, regional, and national level: Data from the Global Burden of Disease study 2019. BMC Public Health. 2021;21:894.
26. Rosenblum H.G., Lewis R.M., Gargano J.W., Querec T.D., Unger E.R., Markowitz L.E. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine United States, 2003–2018. MMWR Morb. Mortal. Wkly. Rep. 2021;70:415–420.
27. Safaeian M., Sampson J.N., Pan Y., Porras C., Kemp T.J., Herrero R., Quint W., van Doorn L.J., Schussler J., Lowy D.R., et al. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. J. Natl. Cancer Inst. 2018;110:205–212.
28. Zizza A., Banchelli F., Guido M., Marotta C., Di Gennaro F., Mazzucco W., Pistotti V., D’Amico R. Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: A systematic review and meta-analysis. Sci. Rep. 2021;11:4954.
29. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N. Engl. J. Med. 2007;356:1915–1927.
30. Muñoz N., Manalastas R., Jr., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., Clavel C., Luna J., Myers E., Hood S., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet. 2009;373:1949–1957.
31. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., Sauvageau C., Scheifele D.W., Kollmann T.R., Halperin S.A., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA. 2013;309:1793–1802.
32. McCormack P.L., Joura E.A. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women. BioDrugs. 2011;25:339–343.
33. Steinau M., Unger E.R., Hernandez B.Y., Goodman M.T., Copeland G., Hopenhayn C., Cozen W., Saber M.S., Huang Y., Peters E.S., et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J. Low. Genit. Tract Dis. 2013;17:397–403.
34. Canadian Immunization C. Summary of Canadian Immunization Committee (CIC) Recommendations for Human Papillomavirus Immunization Programs. Can. Commun. Dis. Rep. 2014;40:152–153.
35. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Jr., Penny M.E., Aranda C., Vardas E., Moi H., Jessen H., Hillman R., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N. Engl. J. Med. 2011;364:401–411.
36. Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D., Jr., Aranda C., Jessen H., Hillman R., Ferris D., Coutlee F., Stoler M.H., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011;365:1576–1585.
37. Spinner C., Ding L., Bernstein D.I., Brown D.R., Franco E.L., Covert C., Kahn J.A. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics. 2019;143:e20181902.